Valensa will continue to operate as a “limited liability company” in Florida, with Dr. Rudi E. Moerck as president and CEO.
E.I.D.-Parry Ltd. (Chennai, India), the bioproducts and nutraceutical division of the Murugappa Group, has acquired 100% of the voting shares of Valensa International (Eustis, FL). Valensa will continue to operate as a “limited liability company” in Florida, with Dr. Rudi E. Moerck as president and CEO.
In 2008, Parry acquired a 49% stake in Valensa to expand its North American business. For the past three years, the companies have combined their expertise in micro-algal technology and supercritical CO2 extraction to introduce ingredients.
“The cooperation between Parry and Valensa has been outstanding; Valensa has become more than a traditional ingredient supplier,” stated Moerck in a press statement. “The development of Valensa’s Pur Blue SpiruZan (spirulina+astaxanthin) tablets with Parry is a perfect example of the scientific and technological cooperation that continually takes place between the two companies.”
The company says that Pur Blue SpiruZan is the first product of its type that appeals to customers looking for a “taste-enhanced” algae product. “This is a great way for Americans to benefit from a nutritious ‘green’ Spirulina algae product without that typical algae taste. Valensa’s business is now poised to take off, with the company developing science based condition-specific formulated products that address unmet needs in human health,” Moerck stated.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.